Results 61 to 70 of about 12,515 (211)

Multiportal Arthroscopy‐assisted Surgical Resection of Diffuse‐type Tenosynovial Giant Cell Tumors in the Ankle Joint Yields Favorable Clinical Outcomes: A Retrospective Study

Orthopaedic Surgery, Volume 16, Issue 11, Page 2680-2687, November 2024.
Ankle arthroscopy is characterized by its short duration, minimal trauma, and rapid recovery. Moreover, it enables clear visualization of lesions, and with the use of multiportal approaches, complete excision of diffuse‐type tenosynovial giant cell tumors (Dt‐TGCTs) within the ankle joint cavity is feasible.
Jiayao Zhang, Lei Yao, Yiyuan Sun, Junqiao Li, Yunan Hu, Kunhao Chen, Wufeng Cai, Chenghao Zhang, Jian Li, Qi Li   +9 more
wiley   +1 more source

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?

Turkish Journal of Hematology, 2016
INTRODUCTION: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP) release in chronic myeloid leukemia patients. METHODS: Platelet aggregation and ATP release induced by 5.0 mM
Olga Meltem Akay, Fezan Şahin Mutlu, Zafer Gülbaş   +2 more
doaj   +1 more source

Preoperative CT‐based radiomics and deep learning model for predicting risk stratification of gastric gastrointestinal stromal tumors

Medical Physics, Volume 51, Issue 10, Page 7257-7268, October 2024.
Abstract Background Gastrointestinal stromal tumors (GISTs) are clinically heterogeneous with various malignant potential in different individuals. It is crucial to explore a reliable method for preoperative risk stratification of gastric GISTs noninvasively.
Ping Yang, Jiamei Wu, Mengqi Liu, Yineng Zheng, Xiaofang Zhao, Yun Mao   +5 more
wiley   +1 more source

The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Advances in Hematology, 2010
Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec)
K. G. Koffi, D. C. Nanho, E. N'dathz, P. Kouehion, R. Dissieka, A. Attia, K. Mozard, A. Tolo, K. Boidy, N. Meité, R. Ayemou, M. Sekongo, N. Tea, I. Sanogo   +13 more
doaj   +1 more source

Treatment of a feline cutaneous mast cell tumour using imatinib mesylate as a neoadjuvant tyrosine kinase inhibitor therapeutic agent

Veterinární Medicína, 2020
A two-year-old spayed female American shorthair cat presented with a rough, circular, exophytic mass on the genital area. The clinical findings and histopathological examination revealed that the mass contained neoplastic mast cells and, thus, was ...
Joonyoung Kim, Ha-Jung Kim
doaj   +1 more source

A hybrid case of eosinophilic folliculitis and eosinophilic cellulitis associated with hypereosinophilic syndrome

Skin Health and Disease, Volume 4, Issue 5, October 2024.
We report an atypical case of Wells syndrome in conjunction with rare eosinophilic disorders such as hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). Abstract Eosinophilic cellulitis or Wells syndrome encompasses distinct histopathological features but can also be associated with eosinophilic ...
Domniki Iatropoulou, Cathryn Sprenger, Richard Griffiths, Nilukshi Wijesuriya, Bernard Ho   +4 more
wiley   +1 more source

A highly sensitive reporter system to monitor endogenous YAP1/TAZ activity and its application in various human cells

Cancer Science, Volume 115, Issue 10, Page 3370-3383, October 2024.
In this report, a lentivirus‐based reporter cell system using a highly sensitive YAP1/TAZ/TEAD‐responsive DNA element was established. This system provides a versatile tool for assessing the endogenous YAP1/TAZ activity and exploring their novel modulators. Abstract The activation of yes‐associated protein 1 (YAP1) and transcriptional co‐activator with
Hiroki Hikasa, Kohichi Kawahara, Masako Inui, Yukichika Yasuki, Keita Yamashita, Kohei Otsubo, Shojiro Kitajima, Miki Nishio, Kazunari Arima, Motoyoshi Endo, Masanori Taira, Akira Suzuki   +11 more
wiley   +1 more source

Serious Skin Reaction Associated with Imatinib in a Patient with Chronic Myeloid Leukemia

Eurasian Journal of Medicine, 2011
Imatinib mesylate (STI 571) is one of the fundamental chemotherapeutic agents used in the treatment of the chronic, accelerated and blastic phases of chronic myelocytic leukemia (CML), gastrointestinal stromal tumors and Philadelphia chromosome–positive ...
Murat Albayrak, Harika Celebi, Aynur Albayrak, Esra Saribacak Can, Vedat Aslan, Birgul Onec, Ipek Coban   +6 more
doaj  

18FDG-PET at 1-Month Intervals Is a Better Predictive Marker for GISTs That Are Difficult to Be Diagnosed Histopathologically: A Case Report

Case Reports in Oncological Medicine, 2011
Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an effective drug that can be used as a first-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
Kazunori Otsuka, Masahiro Takahashi, Hiroshi Nanjo, Hideaki Miyazawa, Masatake Iida, Yuki Abe, Mario Jin, Hirohide Onishi, Manabu Hashimoto, Yuzo Yamamoto, Hiroyuki Shibata   +10 more
doaj   +1 more source

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

Haematologica, 2008
Background Imatinib mesylate is the first line treatment for chronic myeloid leukemia. In patients with advanced phase of the disease, the advent of imatinib significantly increased survival.
Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Luatti, Giulia Marzocchi, Simona Bassi, Massimo Breccia, Giuliana Alimena, Ester Pungolino, Giovanna Rege-Cambrin, Riccardo Varaldo, Maurizio Miglino, Giorgina Specchia, Eliana Zuffa, Felicetto Ferrara, Monica Bocchia, Giuseppe Saglio, Fabrizio Pane, Daniele Alberti, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti   +21 more
doaj   +1 more source